Athersys to Present at BIO CEO & Investor Conference

Athersys to Present at BIO CEO & Investor Conference

CLEVELAND, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX)
announced today that Gil Van Bokkelen, Ph.D., Chairman and Chief Executive
Officer, will present at the 15^th Annual BIO CEO & Investor Conference to be
held Monday, February 11, 2013, through Tuesday, February 12, 2013, at The
Waldorf Astoria New York in New York City.

Details of Athersys' participation are as follows:

Event:     15^th AnnualBIO CEO & Investor Conference
Date:     Tuesday, February 12, 2013
Time:     9:00 a.m. Eastern Standard Time
Location:  The Waldorf Astoria New York

The 15th Annual BIO CEO & Investor Conference assembles a select group of
established biotech companies, as well as top public and private equity
investors and members of the sell-side investment community, to explore the
current investment landscape and opportunities in life sciences. In addition
to plenary sessions and panel discussions on timely business topics and key
therapeutic areas, the conference features presentations by over 130 leading
biotechnology and pharmaceutical companies, as well as a number of nonprofit
and venture philanthropy organizations.

About Athersys

Athersys is a clinical stage biotechnology company engaged in the discovery
and development of therapeutic product candidates designed to extend and
enhance the quality of human life. The Company is developing its MultiStem^®
cell therapy product, a patented, adult-derived "off-the-shelf" stem cell
product platform for disease indications in the cardiovascular, neurological,
inflammatory and immune disease areas. The Company currently has several
clinical stage programs involving MultiStem, including for treating
inflammatory bowel disease, ischemic stroke, damage caused by myocardial
infarction, and for the prevention of graft-versus-host disease. Athersys has
also developed a diverse portfolio that includes other technologies and
product development opportunities, and has forged strategic partnerships and
collaborations with leading pharmaceutical and biotechnology companies, as
well as world-renowned research institutions in the United States and Europe
to further develop its platform and products. More information is available at

The Athersys, Inc. logo is available at

CONTACT: William (B.J.) Lehmann, J.D.
         President and Chief Operating Officer
         Tel: (216) 431-9900
         Investor Relations:
         Lisa M. Wilson
         In-Site Communications
         Tel: (917) 543-9932

company logo
Press spacebar to pause and continue. Press esc to stop.